Open-label trial of atomoxetine hydrochloride in adults with ADHD

Journal of Attention Disorders

Volumn 13, Issue 5, 2010, Pages 539-545

  Johnson, Mats ^a   Cederlund, Mats ^a   Råstam, Maria ^a,b   Areskoug, Björn ^a   Gillberg, Christopher ^a,c,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ADHD; Adults; Atomoxetine; Long term trial

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATIENT SELECTION; TIME; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SELECTION; PROPYLAMINES; TIME; TREATMENT OUTCOME;

EID: 77649247794     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054709332372     Document Type: Article

References (18)

1. Adler, L.A., Spencer, T.J., Levine, L.R., Ramsey, J.L., Tamura, R., Kelsey, D.et al.(2008). Functional outcomes in the treatment of adults with ADHD. Journal of Attention Disorders, 11, 720-727.
2. Adler, L.A., Spencer, T.J., Milton, D.R., Moore, R.J. & Michelson, D. (2005). Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis. Journal of Clinical Psychiatry, 66, 294-299.
3. Adler, L.A., Spencer, T.J., Williams, D.W., Moore, R.J. & Michelson, D. (2008). Long-term, Open-label safety and efficacy of atomoxetine in adults with ADHD. Journal of Attention Disorders, 12, 248-253.
4. Adler, L.A., Sutton, V.K., Moore, R.J., Dietrich, A.P., Reimherr, F.W., Sangal, R.B.et al.(2006). Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Journal of Clinical Psychopharmacology, 26, 648-652.
5. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: Author.
6. Anckarsater, H., Stahlberg, O., Larson, T., Hakansson, C., Jutblad, S.B., Niklasson, L.,et al.(2006). The impact of ADHD and autism spectrum disorders on temperament, character, and personality development. American Journal of Psychiatry, 163, 1239-1244.
7. Barkley, R.A., Anderson, D.L., & Kruesi, M. (2007). A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. Journal of Attention Disorders, 10, 306-316.
8. Buitelaar, J.K., Michelson, D., Danckaerts, M., Gillberg, C., Spencer, T.J., Zuddas, A.,et al.(2007). A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biological Psychiatry, 61, 694-699.
9. Chamberlain, S.R., Del Campo, N., Dowson, J., Müller, U., Clark, L., Robbins, T.W.,et al.(2007). Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry, 62, 977-984.
10. Conners, C.K., Erhardt, D., & Sparrow, E. (1999). Conners' Adult ADHD Rating Scale (CAARS). North Tonawanda, NY: Multi-Health Systems.
11. DuPaul, G.J., Power, T.J., Anastopoulos, A.D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford Press.
12. Gillberg, C., Gillberg, I.C., Råstam, M., & Wentz, E. (2001). The Asperger Syndrome (and high-functioning autism) Diagnostic Interview (ASDI): A preliminary study of a new structured clinical interview. Autism, 5, 57-66.
13. Guy, W. (1976). ECDEU assessment manual for psychopharmacology (Revised). Bethesda, MD: US Department of Health, Education, and Welfare.
14. Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Psychiatry, 32, 50-55.
15. Leon, A.C., Olfson, M., Portera, L. Farber, L., & Sheehan, D.V. (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. International Journal of Psychiatry in Medicine, 27, 93-105.
16. Michelson, D., Adler, L., Spencer, T., Reimherr, F.W., West, S.A., Allen, A.J.,et al.(2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120.
17. Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J.et al.(1998). Effectiveness and tolerability of Tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155, 693-695.
18. Svanborg, P. and Åsberg, M. (2001). A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord 64, 203-216.